Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

318.46USD
22 Sep 2017
Change (% chg)

$3.43 (+1.09%)
Prev Close
$315.03
Open
$311.30
Day's High
$319.34
Day's Low
$311.30
Volume
988,033
Avg. Vol
1,401,481
52-wk High
$330.00
52-wk Low
$244.28

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $67,332.55
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-Biogen appoints Sanjay Jariwala as SVP

* Biogen appoints Sanjay Jariwala as SVP, worldwide medical Source text for Eikon: Further company coverage:

Sep 12 2017

BRIEF-Ionis earns $40 million Spinraza regulatory milestone payment from Biogen

* Ionis earns $40 million Spinraza regulatory milestone payment from Biogen

Aug 30 2017

Samsung, Biogen version of AbbVie's Humira approved in Europe

A biosimilar version of AbbVie Inc's blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc and Samsung Biologics, was approved by European Union regulators, the partners said on Thursday.

Aug 25 2017

UPDATE 1-Samsung, Biogen version of AbbVie's Humira approved in Europe

Aug 24 A biosimilar version of AbbVie Inc's blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc and Samsung Biologics , was approved by European Union regulators, the partners said on Thursday.

Aug 25 2017

BRIEF-Imraldi, Biogen's Adalimumab Biosimilar referencing Humira, is approved in EU

* Imraldi(®), Biogen's Adalimumab Biosimilar referencing Humira(®), is approved in European Union

Aug 24 2017

BRIEF-Paulson & Co takes share stake in Apple, dissolves share stake in Sarepta, Biogen

* Ups share stake in T-Mobile US Inc by 46.1 percent to 6.1 million shares - SEC filing

Aug 14 2017

BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene

* Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares

Aug 14 2017

BRIEF-Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences

* Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences Source text for Eikon: Further company coverage:

Jul 31 2017

BRIEF-Abarca Health signs reimbursement contract with Biogen for select products

* Signed value-based reimbursement contract with Biogen for select products in Biogen's leading multiple sclerosis portfolio​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Jul 27 2017

BRIEF-Biogen says in July 2017 learned that prosecution office of Milan is investigating interactions with some healthcare providers in Italy - SEC Filing

* Biogen says in July 2017 learned that prosecution office of Milan is investigating interactions with some healthcare providers in Italy - SEC Filing

Jul 25 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $131.39 -0.36
Pfizer Inc. (PFE.N) $35.96 -0.01
Novartis AG (NOVN.S) CHF83.45 +0.50
Merck & Co., Inc. (MRK.N) $65.13 -0.47
Roche Holding Ltd. (ROG.S) CHF248.00 -1.00
Roche Holding Ltd. (RO.S) CHF248.00 -1.00
Bayer AG (BAYGn.DE) €110.10 -0.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €84.12 +0.25
GlaxoSmithKline plc (GSK.L) 1,474.00 +6.00

Earnings vs. Estimates